ctDNA as a cancer biomarker: A broad overview
LS Pessoa, M Heringer, VP Ferrer - Critical reviews in oncology …, 2020 - Elsevier
Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …
[HTML][HTML] “Liquid biopsy”—ctDNA detection with great potential and challenges
M Ma, H Zhu, C Zhang, X Sun, X Gao… - Annals of translational …, 2015 - ncbi.nlm.nih.gov
Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive “real-
time” biomarker that can provide diagnostic and prognostic information before, during …
time” biomarker that can provide diagnostic and prognostic information before, during …
[HTML][HTML] Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
F Cheng, L Su, C Qian - Oncotarget, 2016 - ncbi.nlm.nih.gov
Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …
Translational application of circulating DNA in oncology: review of the last decades achievements
NO Tuaeva, L Falzone, YB Porozov, AE Nosyrev… - Cells, 2019 - mdpi.com
In recent years, the introduction of new molecular techniques in experimental and clinical
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …
Circulating tumor DNA: current challenges for clinical utility
DK Dang, BH Park - The Journal of clinical investigation, 2022 - Am Soc Clin Investig
Cancer cells shed naked DNA molecules into the circulation. This circulating tumor DNA
(ctDNA) has become the predominant analyte for liquid biopsies to understand the …
(ctDNA) has become the predominant analyte for liquid biopsies to understand the …
Advances in circulating tumor DNA analysis
The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might
revolutionize cancer care with respect to early detection, identification of minimal residual …
revolutionize cancer care with respect to early detection, identification of minimal residual …
[HTML][HTML] Liquid biopsy: Potential and challenges
K Pantel, C Alix‐Panabières - Molecular oncology, 2016 - ncbi.nlm.nih.gov
Current molecular diagnostics in cancer patients is based on needle biopsies, which,
however, face serious limitations which can lead to false decisions. Individual tumors consist …
however, face serious limitations which can lead to false decisions. Individual tumors consist …
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
[HTML][HTML] Considerations and quality controls when analyzing cell-free tumor DNA
Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive
technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to …
technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to …
[HTML][HTML] Liquid biopsy in tumors: opportunities and challenges
Y Bai, H Zhao - Annals of translational medicine, 2018 - ncbi.nlm.nih.gov
The emergence of non-invasive diagnostic techniques for tumors (1), such as liquid biopsy,
marks a major step forward for humans on the road to conquering tumors. From the 2016 …
marks a major step forward for humans on the road to conquering tumors. From the 2016 …